improved resolution of the genomic scan, while its sensitivity remains comparable to that of MC. As a result, the proportion of patients with normal karyotype decreased compared to routine MC, and more patients showed multiple lesions. It is likely that the presence of additional changes as detected by SNP-A analysis is responsible for the variability of the clinical phenotype associated with a known karyotype. Of significant interest is that regions of UPD detected by SNP-A were also located in portions of chromosomes frequently affected by genomic losses. We suggest that SNP-A constitutes a major advance in comparison to MS-based identification of LOH. Theoretically, the resolution of SNP-A is limited only by the number of SNP probes used, while its sensitivity depends on the contribution of the dysplastic clone to the overall cellular content of the sample. One major advantage of SNP-A is the ability to perform analyses on interphase cells without the need for cell division. This advantage is reflected by the low proportion of non-informative results. Unlike traditional MC, SNP-A do not allow for the distinction of multiple clones and minor clones may remain undetected due the 'dilution' effect. In general, SNP-A showed very good correlation with MC. However, in a proportion of patients lesions detected by MC were not found by SNP-A. This discrepancy is due to various reasons, including the fact that loss of Y is not tested on the array and balanced translocations and inversions cannot be detected by this technique. Finally, the remaining discrepancy is due to lower sensitivity of SNP-A for smaller clones.
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Our analysis was performed using total bone marrow. Sorted myeloid cells were not available but it is likely that lymphocyte depletion would result in a higher detection rate. Despite this shortcoming, clonal lesions were detected and the fact that the defects were seen despite the contamination suggests that the clones detected were of significant size. While this clearly decreases the sensitivity, it may be an advantage as only large likely clinically significant clones were studied.
In sum, we have written this letter as we believe that SNP-Abased karyotyping is a technology that should be further explored as it may complement metaphase karyotyping in improved prediction of clinical phenotype and prognosis in the diagnosis of MDS and allow for better mapping of the breakpoints. To our knowledge, our letter describes the first systematic application of this technology in MDS. We hope that we can inspire further investigations and discussion on innovative ways to improve cytogenetic diagnosis of MDS. Human cells are frequently exposed to DNA double-strand breaks (DSB) that are generated either by endogenous (for example, V(D)J recombination and reactive oxygen species) or by exogenous (for example, ionizing radiation and chemotherapy regimens) agents. To repair DSB and maintain genome integrity, human cells have evolved two major repair pathways: non-homologous end-joining (NHEJ) and homologous recombination (HR). HR uses homologous DNA strand as a template to repair DSB and is an error-free process. 1 NHEJ repairs DSB by directly re-ligating DNA ends, which may be error-prone and may produce mis-ligation between the two chromosome ends. [2] [3] [4] In this regard, it has been shown that NHEJ repair is involved in the generation of certain chromosomal translocations in acute myeloid and lymphoid leukemia.
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2,3,5 These chromosome translocations are thought to be correlated with highly activated NHEJ activity. 2, 3 However, the expressions of NHEJ genes in these tumors are poorly understood so far. In this study, we report a survey of NHEJ mRNA expressions in pediatric acute lymphoblastic leukemia (ALL).
To investigate a panel of NHEJ gene expressions in pediatric ALL, we examined mRNA transcripts of all NHEJ family members, including Ku70, Ku80, DNA-PK, Artemis, XRCC4, DNA ligase IV and the newly identified Cernunnos/XLF 6,7 by real-time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). The bone marrow or peripheral blood specimens were collected from various disease statuses, which were untreated fresh ALL (n ¼ 11), complete remission (n ¼ 7) and relapsed cases (n ¼ 5). Thalassemia specimens (n ¼ 9) were used as a reference to compare NHEJ mRNA expressions with pediatric ALL. All specimens were collected after obtaining patients' informed consents. The mononuclear cells in these specimens were purified by standard Ficoll-Hypaque sedimentation and then subjected to RNA isolation and qRT-PCR analysis by using b-actin as an internal control. The PCR primers used in this study are shown in Table 1 . For each specimen, at least two independent qRT-PCR experiments were performed for all NHEJ genes. Since each NHEJ mRNA expression was relatively consistent between various thalassemia samples ( Figure 1 , column 'T' of each panel), the mean expression of each NHEJ mRNA in thalassemia samples was set as one and used to compare with those in pediatric ALL specimens. We found that mRNA expressions of all NHEJ members were elevated in untreated fresh ALL when compared with thalassemia cases (Figure 1 , columns 'ALL' and 'T' of each panel). Overexpressed NHEJ mRNAs were downregulated after therapy (Figure 1 , column 'CR'). However, mRNA transcripts of Ku80, DNA-PK, Artemis, XRCC4 and DNA ligase IV were elevated again in relapsed specimens (Figure 1 , column 'Relapse').
In addition to differential mRNA expressions of NHEJ genes found between persons of various disease statuses (ALL, CR and relapse), data obtained from the same individual sampled at different disease stages showed similar patterns of NHEJ mRNA expressions (Figure 2a ). This pattern could be easily found if all NHEJ genes were considered simultaneously (Figure 2b and c) . By setting the above fivefold mRNA elevation as a high expression, one could determine the numbers of NHEJ genes with high expression for each specimen. We classified each patient for each qRT-PCR experiment into two groups by this criterion. One has more than half of analyzed NHEJ genes with high expression and the other has less than half. Figure 2d shows an opposite distribution of NHEJ mRNA expressions between leukemic (ALL and relapse) and non-leukemic (thalassemia and 
Figure 1
Messenger RNA expressions of NHEJ genes in pediatric acute lymphoblastic leukemia (ALL) and thalassemia. For comparison of thalassemia (T, n ¼ 9), samples of pediatric ALL were collected from untreated fresh (ALL, n ¼ 11), complete remission (CR, n ¼ 7) and relapse (relapse, n ¼ 5) cases. RNA was isolated by Tri-reagent (Sigma-Aldrich, St Louis, MO, USA) and was reverse transcribed by SuperScript III reverse transcriptase (Invitrogen, Carlsbad, CA, USA). Real-time quantitative PCR was conducted by Platinum SYBR Green qPCR SuperMix UDG with ROX kit (Invitrogen) in 20 ml and ABI Prism 7500 Sequence Detection System instrument (Applied BioSystems, Foster City, CA, USA). The PCR primer sequences are listed in Table 1 . Cycling conditions were 501C for 10 s and 951C for 2 min followed by 50 cycles at 951C for 15 s and 601C for 1 min. Dissociation curve was added at the final step to ensure that only the specific target was amplified in the PCR reaction. The resulting data were analyzed by SPSS software and shown as box plots that consisted of, at least, two independent experiments for each sample. The boxes in the figures represent upper and lower quartiles, and the median of each category is shown. Differential RNA expressions between various samples were calculated by 2 ÀDDCT method 9 and using b-actin as an internal control.
CR) samples. These results suggested that overexpressions of NHEJ mRNAs were closely associated with leukemic cells.
To examine further the association between overexpressions of NHEJ genes and hematopoietic cancers, we compared NHEJ mRNA expressions in malignant cell lines (K562 and BJAB) and in peripheral blood mononuclear cells (PBMC) of healthy donors (n ¼ 5). As shown in Figure 3a , Ku70, Ku80 and DNA-PK expressed about 10-fold higher in K562 and BJAB than in PBMC or thalassemia specimens. The Artemis, Cernunnos/XLF, XRCC4 and DNA ligase IV also overexpressed, but less than 10-fold, in the two established cancer cell lines (Figure 3a) . These data suggested that NHEJ mRNAs also overexpressed in certain hematopoietic cancer cell lines. In addition to leukemia, Ku70, Ku80 and DNA-PK are also upregulated in colorectal cancer. 8 It is thought that this elevation of NHEJ gene expression reflects the requirement of DNA repair activity in highly proliferated cells. To know whether NHEJ genes usually overexpress in human malignancies, we examined NHEJ mRNA expressions in 11 paired oral carcinomas and corresponsive normal tissues. As shown in Figure 3b , we did not find elevated mRNA expressions of any NHEJ member in oral cancer tissues. These results indicated a distinct role of NHEJ repair between pediatric ALL and oral cancer.
In summary, we show here that mRNA expressions of NHEJ genes were upregulated in pediatric ALL. To our knowledge, this Letters to the Editor study is the first to present the mRNA expression of Cernunnos/ XLF, which was newly identified as an NHEJ member in 2006, 6, 7 as well as of other NHEJ components including Artemis, XRCC4 and DNA ligase IV in pediatric ALL. We showed that overexpressions of NHEJ genes were closely associated with malignant leukemic cells, since elevations of NHEJ mRNA transcripts were found only in fresh ALL and in relapsed cases, but not in thalassemia, complete remission or peripheral blood of normal individuals. Elevations of NHEJ mRNAs could also be found in malignant cell lines K562 and BJAB, but not in oral cancer. Therefore, we propose that upregulation of NHEJ mRNA transcripts is a characteristic of pediatric ALL. This feature may be valuable for proper prognosis or for providing strategies for treatment of this malignancy.
